Search Results
Your search for ,foR matches 32687 pages
Showing 29501 - 29550
Alysa M. Fairchild, MD, on Preventing Radiation-Induced Pain Flare
Alysa M. Fairchild, MD, of the Cross Cancer Institute and the University of Alberta, discusses her study on the use of dexamethasone to reduce pain flare in patients receiving palliative radiotherapy for bone metastases (Abstract LBA6663).
Even Before Affordable Care Act, Cancer Survivors in Nonexpansion States Had Less Health-Care Access
An analysis published by Tarazi et al in the Journal of Cancer Survivorship found that even in the health-care landscape before the Affordable Care Act, cancer survivors in states that had already expanded Medicaid coverage prior to passage of the Act had more access to health care than cancer...
More Than One-Third of Patients With Metastatic Cancer Continue to Work
A new analysis indicated that many patients continue working after being diagnosed with metastatic cancer, but a heavy burden of symptoms may prevent them from doing so. Published by Tevaarwerk et al in Cancer, the study illustrates the need to treat difficult symptoms so that patients can maintain ...
Stereotactic Body Radiotherapy vs Radiofrequency Ablation in Inoperable Nonmetastatic Hepatocellular Carcinoma
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Wahl et al found that stereotactic body radiotherapy may provide better freedom from local tumor progression vs radiofrequency ablation in patients with inoperable nonmetastatic larger hepatocellular...
Patient-Reported Outcomes With Adjuvant Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
As reported in The Lancet and at the recent San Antonio Breast Cancer Symposium, Ganz et al found differences in patient-reported outcomes with anastrozole vs tamoxifen in the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial in postmenopausal women with hormone...
Jack Cuzick, PhD, FMedSci, on DCIS Recurrence Rates: Anastrozole vs Tamoxifen
Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen or anastrozole for 5 years after surgery. (Abstract S6-03)
Andrew Seidman, MD, and Erica Mayer, MD, MPH, on Results of the PALLAS Clinical Trial
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Erica L. Mayer, MD, MPH, of the Dana-Farber Cancer Institute, discuss this phase 3 trial of palbociclib with adjuvant endocrine therapy vs endocrine therapy alone for HR-positive/HER2-negative early breast cancer. (Abstract...
Andrew Seidman, MD, and Hope Rugo, MD: Less is More: Scaling Back Breast Cancer Treatment
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings on de-escalating systemic therapy for breast cancer (Abstract ES6-3).
Clifford Hudis, MD, and Carlos Arteaga, MD, on Metabolic Syndrome and Obesity in Breast Cancer
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, adipokines and inflammation, and metformin and lifestyle change in breast cancer and risk for the disease.
Clifford Hudis, MD, and Julia White, MD, on Early-Stage Breast Cancer: Hypofractionated Radiotherapy
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-analysis on efficacy and safety of hypofractionated radiotherapy for the treatment of early-stage breast cancer (Abstract P3-12-15).
Lisa Carey, MD, and Jay Harris, MD, on Critical Decision Making in Radiation Therapy for Breast Cancer
Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.
Gunter von Minckwitz, MD: Early Survival Analysis of GeparSixto
Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Abstract S2-05).
Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data...
Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial
Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using the regimen is beneficial for patients with Burkitt lymphoma (Abstract 342).
James Foran, MD, on Clofarabine for AML: Clinical Trial Results of ECOG-ACRIN and ALFA/Clara
James Foran, MD, of the Mayo Clinic Cancer Center, discusses two key studies on clofarabine: as a single agent for induction and postremission therapy in newly diagnosed AML, and as the basis for consolidation in nonfavorable AML (Abstracts 217 and 218).
Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine
Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).
Alok A. Khorana, MD, on Preventing Venous Thromboembolism
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).
Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients
Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).
Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease ...
S. Vincent Rajkumar, MD, on Advances in Myeloma
S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes his education session on the evolving diagnostic criteria for myeloma, which focused on smoldering disease and when it becomes an “open flame.”
David Henry, MD, on Multiple Myeloma: Expert Perspective
David Henry, MD, of Pennsylvania Hospital, discusses the exciting developments in multiple myeloma treatment, including the three new drugs approved for the disease in November 2015.
Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results
Andrew J. Davies, MRCP, PhD, of the Cancer Research UK Centre, University of Southampton, discusses a study of targeted treatment for diffuse large B-cell lymphoma based on real-time gene-expression profiling (Abstract 812).
Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II...
ESMO Asia 2015: Results From the KEYNOTE-010 Trial Show Pembrolizumab Benefit in Patients With NSCLC
More patients with advanced non–small cell lung cancer (NSCLC) could benefit from pembrolizumab (Keytruda), said Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven. Dr. Herbst presented promising results from the pivotal phase...
ESMO Asia 2015: Cancer Drives Patients to Poverty in Southeast Asia
Five percent of cancer patients and their families were pushed into poverty in Southeast Asia between March 2012 and September 2013 because of high disease-related costs, a study (Abstract 52O) by Bhoo-Pathy et al at the European Society for Medical Oncology (ESMO) Asia 2015 Congress in Singapore...
ESMO Asia 2015: Immunotherapy and Targeted Therapy Provide New Options for Difficult-to-Treat Head and Neck Cancer
Novel strategies are being explored for difficult-to-treat and advanced head and neck cancer—the most heterogeneous group of malignancies that are generally associated with poor survival—and encouraging results have been presented in two trials at the first European Society for Medical...
ESMO Asia 2015: Afatinib a Better Choice for EGFR-Mutated Lung Cancer in First-Line Treatment
Patients with epidermal growth factor receptor (EGFR)-activating mutations in advanced lung cancer seem to benefit more from afatinib (Gilotrif) than gefitinib (Iressa) as first-line treatment, Park et al reported in a study (Abstract LBA2) presented at the European Society for Medical Oncology...
FDA Expands Pembrolizumab Label to Include Approval in Initial Treatment of Unresectable or Metastatic Melanoma
On December 18, 2015, the U.S. Food and Drug Administration (FDA) expanded the pembrolizumab (Keytruda) label to include approval of the drug for the treatment of patients with unresectable or metastatic melanoma. This expansion now includes the initial treatment of patients with unresectable or...
Periodontal Disease Linked to Increased Risk of Breast Cancer in Postmenopausal Women, Especially Smokers
A large prospective study of postmenopausal women investigating an association between periodontal disease and breast cancer risk has found that among all women in the study, the risk of breast cancer was 14% higher in women who had periodontal disease. Among women who had quit smoking within the...
Follow-up Times for Colorectal Cancer Screening Abnormalities Lag Behind Others
Follow-up times of abnormal screening exams were shorter for breast cancer than they were for colorectal and cervical cancers, according to a recent study involving more than 1 million individuals who underwent these screenings. Recently published by Tosteson et al in the Journal of General...
Mental Health Status Prior to Radical Cystectomy Can Indicate Risk of Complications
A patient's mental health prior to surgery can influence postoperative outcomes. Removal of the bladder, or radical cystectomy, is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66% of patients. In a study published by Sharma et al in The Journal...
Characterization of Pathogenic Mutations in Melanoma Progression
In a study reported in The New England Journal of Medicine, Shain et al identified the order of occurrence of mutations in the progression of melanoma as well as characterized point mutation burden and chromosomal instability during disease evolution. Study Details The study involved sequencing...
Potential Overdiagnosis of Contralateral Breast Cancer With Preoperative Magnetic Resonance Imaging in Older Women With Breast Cancer
In an analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare database reported in the Journal of Clinical Oncology, Wang et al found that use of preoperative magnetic resonance imaging (MRI) was associated with overdiagnosis of contralateral breast cancer among older...
Swedish Screening Model Improves Performance of Prostate Cancer Screening vs PSA Alone in Men Aged 50–69 Years
In a Swedish study reported in The Lancet Oncology (Stockholm 3 study), Grönberg et al found that a screening model including prostate-specific antigen (PSA) and other plasma protein markers, genetic polymorphisms, and clinical variables improved the accuracy of detecting prostate cancer with...
Fractionated Stereotactic Radiation More Effective Than Single-Dose Radiation in Pituitary Tumors
A recent study at Houston Methodist Hospital proved that multiple small doses of highly focused radiation therapy is safer and more effective than a single larger dose of radiation at destroying pituitary gland tumors. The findings on the use of fractionated stereotactic radiotherapy were published ...
Higher BMI Associated With Increased Risk of Breast Cancer–Related Lymphedema
Each year, about 1.38 million women worldwide are diagnosed with breast cancer. Advances in treatment have facilitated a 90% 5-year survival rate among those treated. Given the increased rate and length of survival following breast cancer, more and more survivors are facing a lifetime risk of...
Study Finds NSCLC to Be Genetically Different in Younger and Older Patients, Requiring Different Treatment Approaches
Unlike a number of other cancers in which young age at diagnosis is understood to represent distinct disease biology, the genomics and clinical characteristics of non–small cell lung cancer (NSCLC) in young patients are poorly understood. A study by Sacher et al investigating the relationship ...
Bruce E. Johnson, MD, FASCO, Elected ASCO President for 2017–2018 Term
Bruce E. Johnson, MD, FASCO, has been elected President of ASCO for the term beginning in June 2017. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2016. Additionally, four new members were elected to the ASCO Board of Directors, as well as three new...
Access to Minimally Invasive Hysterectomies in Early Uterine Cancer Remains Persistently Limited
A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer...
New ‘Condensed’ Grading System Shown to Be Accurate for Predicting Prostate Cancer Outcomes
Using information gleaned from more than 20,000 men, researchers at Johns Hopkins have affirmed the value of their alternative system for assessing the likelihood of growth and spread of prostate cancer. The new grading system, they said, is not only easier to use and understand, but also more...
Adding Ibrutinib to Bendamustine/Rituximab Increases Progression-Free Survival in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In the phase III HELIOS trial, reported in The Lancet Oncology, Chanan-Khan et al found that adding the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increased progression-free survival in patients with chronic lymphocytic leukemia or...
Similar Outcomes Reported With Surgery vs Definitive Concurrent Chemoradiotherapy in Resectable Stage III NSCLC
Findings in an early-terminated German phase III trial (ESPATUE), reported in the Journal of Clinical Oncology by Eberhardt et al, indicate similar outcomes with surgery vs definitive concurrent chemoradiotherapy after induction chemotherapy and chemoradiotherapy in patients with resectable stage...
Patients With Thyroid Cancer Report Poor Quality of Life Despite ‘Good’ Diagnosis
Thyroid cancer survivors report poor quality of life after diagnosis and treatment compared with other patients who are diagnosed with more lethal cancers, according to new research from the University of Chicago Medicine. The findings, published by Aschebrook-Kilfoy et al in the journal Thyroid,...
Preoperative Use of Blood-Thinning Drugs Is Safe for Patients With Cancer
Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published by Selby et al in the Journal...
Treatment Trends in Stage II and III Colorectal Cancer in the United States
As reported by Murphy et al in the Journal of the National Cancer Institute, an analysis of Surveillance, Epidemiology, and End Results (SEER) data from patients with stage II or III colorectal cancer indicated that the use of adjuvant chemotherapy in colon cancer declined slightly between 2005 and ...
Moore Scoring System Helps Identify Women With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab
Previously published reports from the randomized phase III Gynecologic Oncology Group (GOG) protocol 240 clinical trial showed that adding bevacizumab (Avastin) to a chemotherapy regimen of paclitaxel plus cisplatin or topotecan significantly increased overall survival and progression-free survival ...
HDAC Inhibitors May Help Prevent Cisplatin-Based Kidney Damage
A class of drugs used increasingly to help fight cancer may have the additional benefit of protecting the kidneys when packaged with the powerful chemotherapy agent cisplatin. These findings were published by Ranganathan et al in Kidney International. The nearly 40-year-old cisplatin can be a...
FDA Allows Marketing of Cooling Cap to Reduce Hair Loss During Chemotherapy
The U.S. Food and Drug Administration has cleared the first cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy for marketing in the United States. Hair loss is a common side effect of certain types of chemotherapy, commonly associated with the treatment of...
Germline ETV6 Variations as Basis of Novel Genetic Syndrome Associated With Childhood Acute Lymphoblastic Leukemia
In a systematic genetic study reported in The Lancet Oncology, Moriyama et al found that germline ETV6 variations identified in a small proportion of children with acute lymphoblastic leukemia (ALL) were associated with a novel syndrome predisposing carriers to disease. Recent data indicated that...
Carpal Tunnel Syndrome in Patients Treated With Anastrozole in IBIS-II
As reported by Spagnolo et al in the Journal of Clinical Oncology, women receiving anastrozole in the International Breast Cancer Intervention Study II (IBIS-II) had a higher incidence of carpal tunnel syndrome compared with those receiving placebo. A higher incidence of carpal tunnel syndrome...
